search
Back to results

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin
Sponsored by
Boryung Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hypertension focused on measuring Fimasartan

Eligibility Criteria

19 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Caucasian male 19-55 years of age.
  2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
  3. Medically healthy with no clinically significant medical history.
  4. Understands the study procedures in the Informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

  1. History or presence of clinically significant medical or psychiatric condition or disease.
  2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
  3. Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at screening.
  4. Plasma donation within 7 days prior to the first dose of study drug.
  5. Participation in another clinical trial within 28 days prior to the first dose of study drug(s).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm Type

    Other

    Other

    Other

    Other

    Other

    Other

    Arm Label

    Sequence 1 (ABC)

    Sequence 2 (ACB)

    Sequence 3 (BAC)

    Sequence 4 (BCA)

    Sequence 5 (CAB)

    Sequence 6 (CBA)

    Arm Description

    Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C) There will be a washout of at least 7 days between the each period.

    Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B) There will be a washout of at least 7 days between the each period.

    Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3) There will be a washout of at least 7 days between the each period.

    Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A) There will be a washout of at least 7 days between the each period.

    Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B) There will be a washout of at least 7 days between the each period.

    Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A) There will be a washout of at least 7 days between the each period.

    Outcomes

    Primary Outcome Measures

    Area Under the Concentration-time Curve
    This Outcome is the Area Calculated using the Linear Trapezoidal with Linear Interpolation Method
    Maximum Observed Concentration
    This Outcome is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated.
    Time to Reach Maximum Observed Plasma Concentration
    This Outcome is the time it takes a drug to reach Cmax

    Secondary Outcome Measures

    Full Information

    First Posted
    March 4, 2016
    Last Updated
    February 5, 2018
    Sponsor
    Boryung Pharmaceutical Co., Ltd
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02704702
    Brief Title
    A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2016 (undefined)
    Primary Completion Date
    June 2016 (Actual)
    Study Completion Date
    June 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boryung Pharmaceutical Co., Ltd

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.
    Detailed Description
    This is an open-label, randomized, 6-sequence, 3-period, 3-way crossover study. Within each period, randomized subjects will be 2 dosing regimens with the same drug(fimasartan or rosuvastatin) or study drug combination(fimasartan+rosuvastatin) on day 1 and quaque die(qd) from day 4 to day 10. After day 1 and day 10 dosing will be followed by pharmacokinetic sampling for 48 hours or 72 hours.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension
    Keywords
    Fimasartan

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    36 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sequence 1 (ABC)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C) There will be a washout of at least 7 days between the each period.
    Arm Title
    Sequence 2 (ACB)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B) There will be a washout of at least 7 days between the each period.
    Arm Title
    Sequence 3 (BAC)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3) There will be a washout of at least 7 days between the each period.
    Arm Title
    Sequence 4 (BCA)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A) There will be a washout of at least 7 days between the each period.
    Arm Title
    Sequence 5 (CAB)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B) There will be a washout of at least 7 days between the each period.
    Arm Title
    Sequence 6 (CBA)
    Arm Type
    Other
    Arm Description
    Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A) There will be a washout of at least 7 days between the each period.
    Intervention Type
    Drug
    Intervention Name(s)
    Fimasartan
    Intervention Type
    Drug
    Intervention Name(s)
    Rosuvastatin
    Intervention Type
    Drug
    Intervention Name(s)
    Fimasartan + Rosuvastatin
    Primary Outcome Measure Information:
    Title
    Area Under the Concentration-time Curve
    Description
    This Outcome is the Area Calculated using the Linear Trapezoidal with Linear Interpolation Method
    Time Frame
    For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period
    Title
    Maximum Observed Concentration
    Description
    This Outcome is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated.
    Time Frame
    For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period
    Title
    Time to Reach Maximum Observed Plasma Concentration
    Description
    This Outcome is the time it takes a drug to reach Cmax
    Time Frame
    For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Caucasian male 19-55 years of age. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening. Medically healthy with no clinically significant medical history. Understands the study procedures in the Informed consent form (ICF), and be willing and able to comply with the protocol. Exclusion Criteria: History or presence of clinically significant medical or psychiatric condition or disease. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at screening. Plasma donation within 7 days prior to the first dose of study drug. Participation in another clinical trial within 28 days prior to the first dose of study drug(s).
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Laura Sterling, M.D
    Organizational Affiliation
    Celelion, Inc.
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

    We'll reach out to this number within 24 hrs